The United States Rheumatic Diseases Therapeutics Market

The United States Rheumatic Diseases Therapeutics Market

Changes on the Horizon with Novel Oral Therapies for Musculoskeletal Indications

RELEASE DATE
28-Aug-2012
REGION
North America
Research Code: NAF0-01-00-00-00
SKU: HC02225-NA-MR_07956

$9,000.00

Special Price $6,750.00 save 25 %

In stock
SKU
HC02225-NA-MR_07956

$9,000.00

$6,750.00 save 25 %

DownloadLink

Pay by invoice

ENQUIRE NOW

Description

This research service covers the therapeutics for rheumatic diseases market in the United States from 2009 to 2017, with 2011 as the base year. The focus of this research is on biologics and other treatments prescribed as add-on therapies for rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS); background standard of care therapies are not covered in this study. Included in the study are products already on the market and products in development as well as patient and revenue forecasts. Market challenges, drivers, and restraints are identified and assessed. The market is segmented by disease indication: RA, PsA, and AS.

Table of Contents

Analysis of the United States Rheumatic Diseases Therapeutics Market

  • Executive Summary and Market Overview

Analysis of the Total Rheumatic Diseases Therapeutics Market

  • Drivers and Restraints
  • Forecasts and Trends
  • Demand Analysis
  • Market Share and Competitive Analysis

Analysis of the Rheumatoid Arthritis Segment

  • Segment Breakdown and Market Engineering Measurements
  • Patient Forecast
  • Pricing Trends and Forecast
  • Revenue Forecast
  • Market Share Analysis

Analysis of the Psoriatic Arthritis Segment

  • Segment Breakdown and Market Engineering Measurements
  • Patient Forecast
  • Pricing Trends and Forecast
  • Revenue Forecast
  • Market Share Analysis

Analysis of the Ankylosing Spondylitis Segment

  • Segment Breakdown and Market Engineering Measurements
  • Patient Forecast
  • Pricing Trends and Forecast
  • Revenue Forecast
  • Market Share Analysis
This research service covers the therapeutics for rheumatic diseases market in the United States from 2009 to 2017, with 2011 as the base year. The focus of this research is on biologics and other treatments prescribed as add-on therapies for rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS); background standard of care therapies are not covered in this study. Included in the study are products already on the market and products in development as well as patient and revenue forecasts. Market challenges, drivers, and restraints are identified and assessed. The market is segmented by disease indication: RA, PsA, and AS.
More Information
No Index Yes
Podcast No
Author Deborah Toscano
Industries Healthcare
WIP Number NAF0-01-00-00-00
Is Prebook No